Viewing nowDirtan Tablet 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201802098 · Approved 2018.05.17 · Insurance code 647205150
Treatment of hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is primarily used to lower blood pressure in patients with essential hypertension. It is also effective for heart failure patients who are intolerant to ACE inhibitors (NYHA Class II to IV). It helps to reduce the risk of mortality in patients with left ventricular dysfunction or decreased contractility after myocardial infarction. Thus, this medication is useful not only for the treatment of hypertension and heart failure but also for the prevention of complications after myocardial infarction.
1. Essential hypertension Take with water during or between meals. It is recommended that the medication be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, an oral dose of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily, and do not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily, after which the dose may be increased over several weeks, according to patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment : No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, this medication should not be administered to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment : In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If doses of 80 mg or higher are administered daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age.
This drug may cause serious harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to this medication, pregnant women or women of childbearing potential, nursing mothers, patients with severe liver or kidney disease, and those with a history of certain angioedema should not take this medication. Elderly patients or those with hyperkalemia, mild to moderate liver dysfunction, and patients with cardiovascular conditions should use this medication cautiously, especially since blood pressure may drop rapidly, thus it is recommended to start with a low dose and monitor the condition closely. During treatment, side effects such as headache, dizziness, cough, diarrhea, and fatigue may occur. Rarely, serious adverse reactions such as angioedema, renal impairment, and hyperkalemia may also occur, so consult a doctor immediately if any unusual symptoms occur. If blood pressure becomes too low or if severe dizziness or syncope occurs, the medication should be discontinued and appropriate treatment should be sought, and it is important to regularly monitor kidney function and electrolyte levels during use. Additionally, taking this medication with potassium-sparing diuretics or potassium supplements may lead to dangerously high blood potassium levels, so such combinations should be avoided or carefully managed. This drug may interact with other antihypertensives or certain anti-inflammatory analgesics, so if other medications are being taken, it is essential to inform the healthcare provider. Use in pregnant or nursing women, and in children or adolescents under 18 years old is not recommended as its safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air and moisture. It is also important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.
Oval film-coated tablet colored orange with a grayish tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.